Intravenous immunoglobulin in neurological disorders: a mechanistic perspective.
Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over 25 years. It is a safe preparation with no long-term side effects. IVIg was first demonstrated to be effective in autoimmune disorders, two decades ago, in the treatment of acute immune thrombocytopenia. Since then, the therapeutic efficacy of IVIg has been established in Guillain Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis (MG), dermatomyositis (DM), Kawasaki syndrome and the prevention of graft-versus-host disease in recipients of allogeneic bone marrow transplants and reported in a large number of other autoimmune and systemic inflammatory conditions.
Misra
Namita
N
INSERM U681, Université Pierre et Marie Curie Institut des Cordeliers, 15 rue de l'Ecole de Médecine, Paris, France.
Bayry
Jagadeesh
J
Ephrem
Amal
A
Dasgupta
Suryasarathi
S
Delignat
Sandrine
S
Duong Van Huyen
Jean-Paul
JP
Prost
Fabienne
F
Lacroix-Desmazes
Sebastien
S
Nicoletti
Antonino
A
Kazatchkine
Michel D
MD
Kaveri
Srini V
SV
D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D003165:Complement System Proteins / Q000502:physiology; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D009186:Myelin Sheath / Q000502:physiology; D009422:Nervous System Diseases / Q000628:therapy*; D011961:Receptors, Fc / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology
D001323:Autoantibodies; D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D011961:Receptors, Fc; D003165:Complement System Proteins